Allarity Therapeutics (ALLR)
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet...
- Open
- 1.350
- High
- 1.440
- Low
- 1.350
- Prev. Close
- 1.350
- Volume
- 37.76K
- Turnover
- 52.44K
- Avg Price
- 1.389
- Bid/Ask Ratio
- 88.68%
- Amplitude
- 6.67%
- 52wk High
- 2.350
- Volume Ratio
- 1.56
- Turnover Ratio
- 0.24%
Allarity Therapeutics Analyst Rating
View moreForecast & Rating
Jun 7, 2026Price forecast
$10.25616.78%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Earnings Watch · Aug 14 at 04:13 PM
Allarity Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0
- PUBT · Aug 14 at 07:01 AM
Allarity Therapeutics Q2 FY26 net loss widens to $3.41 million; comprehensive loss narrows to $3.67 million
- PUBT · Jul 7 at 09:01 AM
Allarity Therapeutics secures CLIA certification for in-house DRP testing lab
- PUBT · Jun 30 at 07:04 AM
Allarity Therapeutics wins key US patent for stenoparib DRP companion diagnostic through 2042
- benzinga_article · Jun 22 at 07:05 AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
- PUBT · Jun 22 at 07:11 AM
Allarity Therapeutics to present Phase 2 stenoparib ovarian cancer trial design at ESMO gynecological cancers congress
